Amplia Therapeutics and the Australia New Zealand Gynaecological Group have announced a new ovarian cancer study. ASX-listed Amplia Therapeutics (ASX: ATX) is aggressively broadening its clinical reach, unveiling a major new collaboration to throw its lead drug candidate, narmafotinib, into the ring against ovarian cancer. The company has inked a deal with the Australia New Zealand Gynaecological Oncology Group (ANZGOG) to launch a new clinical study to evaluate its pro

This week’s Bulls N’ Bears ASX Runners of the Week is… Amplia Therapeutics, after the company unveiled results for a potential golden bullet for pancreatic cancer.